Artificial Intelligence in Schizophrenia Spectrum Disorders: Current Use and Future Perspectives. A Systematic Mapping Literature Review
Alpha Psychiatry · 23.04.2026 · 27 (2)
DOI: 10.31083/ap45104 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Alpha Psychiatry, online erschienen am 23.04.2026. Verfasst von Andrea Zucchetti und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Mental Health and Addiction Services, ASST Spedali Civili of Brescia, 25123 Brescia, Italy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Artificial intelligence (AI) techniques are increasingly applied in psychiatric research, yet their use in schizophrenia spectrum disorders (SSDs) remains heterogeneous. This systematic mapping literature review aimed to examine the current applications of AI systems in SSDs. AI approaches were categorized into natural language processing (NLP), machine learning (ML), and deep learning (DL). Key study characteristics were systematically analyzed, including publication year, type of AI algorithm, study population, clinical outcomes, and instrumental techniques. Trends in journal impact factor (IF) were also evaluated.
Methods
A systematic mapping approach was employed to identify and categorize relevant studies investigating AI applications in SSDs. Included studies were analyzed according to predefined evaluation criteria to provide an overview of methodological trends and research focus within the field.
Results
A total of 853 studies met the inclusion criteria. Machine Learning emerged as the most frequently utilized AI approach. AI methods were predominantly applied to diagnostic and differential diagnostic tasks in SSDs. The most commonly employed instrumental techniques were magnetic resonance imaging (MRI) and electroencephalography (EEG). Journal Impact Factor varied significantly across study characteristics, with higher IFs observed in studies focusing specifically on schizophrenia, reporting diagnostic outcomes, or employing MRI or EEG-based measures.
Conclusions
This review represents the first systematic mapping literature review to comprehensively examine AI applications in schizophrenia spectrum disorders. The findings may support clinicians and researchers in planning, implementing, and evaluating AI-based methodologies in SSD research and clinical contexts. Nevertheless, further studies are needed to establish the clinical validity, robustness, and translational applicability of these algorithms.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Mental Health and Addiction Services, ASST Spedali Civili of Brescia, 25123 Brescia, Italy.
- Department of Clinical and Experimental Sciences, University of Brescia, 25121 Brescia, Italy.
ORCID-Profile: Andrea Zucchetti, Viola Bulgari, Cecilia Davini, Michela Gregorelli, Gabriele Nibbio, Stefano Barlati, Antonio Vita
Zitieren
APA
Zucchetti, A., Bulgari, V., Davini, C., Ghio, M., Dosoli, M., Gregorelli, M., Nibbio, G., Barlati, S., & Vita, A. (2026). Artificial Intelligence in Schizophrenia Spectrum Disorders: Current Use and Future Perspectives. A Systematic Mapping Literature Review. Alpha Psychiatry, 27(2). https://doi.org/10.31083/ap45104
Vancouver
Zucchetti A, Bulgari V, Davini C, Ghio M, Dosoli M, Gregorelli M, et al. Artificial Intelligence in Schizophrenia Spectrum Disorders: Current Use and Future Perspectives. A Systematic Mapping Literature Review. Alpha Psychiatry. 2026;27(2). doi:10.31083/ap45104
BibTeX
@article{Zucchetti2026,
author = {Zucchetti, Andrea and Bulgari, Viola and Davini, Cecilia and Ghio, Marco and Dosoli, Marisa and Gregorelli, Michela and Nibbio, Gabriele and Barlati, Stefano and Vita, Antonio},
title = {Artificial Intelligence in Schizophrenia Spectrum Disorders: Current Use and Future Perspectives. A Systematic Mapping Literature Review},
journal = {Alpha Psychiatry},
year = {2026},
volume = {27},
number = {2},
doi = {10.31083/ap45104}
}
EUVIMED